<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04016935</url>
  </required_header>
  <id_info>
    <org_study_id>ONC-010</org_study_id>
    <nct_id>NCT04016935</nct_id>
  </id_info>
  <brief_title>EndoPredict® Extended Endocrine Trial (EXET)</brief_title>
  <official_title>EndoPredict® Extended Endocrine Trial (EXET): A Prospective Registry to Evaluate the Impact of EndoPredict® Test on Extended Endocrine Treatment Decisions and Patient Outcomes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Myriad Genetic Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Myriad Genetic Laboratories, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the impact of using EndoPredict® clinically to&#xD;
      inform treatment decisions for extended endocrine therapy, and the subsequent impact on&#xD;
      patient outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The EndoPredict® molecular test is validated to predict late distant recurrence after 5 years&#xD;
      of endocrine therapy in women with estrogen receptor-positive (ER+), human epidermal growth&#xD;
      factor receptor 2-negative (HER2-) early stage breast cancer, with or without treatment with&#xD;
      adjuvant chemotherapy. The test provides an individualized EPclin score based on the tumor&#xD;
      gene expression, tumor size and nodal status, and categorizes patients as High or Low risk of&#xD;
      distant recurrence.&#xD;
&#xD;
      The primary objective of this study is to evaluate the distant recurrence-free survival&#xD;
      (DRFS) at 5-10 years in patients with ER+/HER2- early stage breast cancer with EPclin Low&#xD;
      scores that did not extend endocrine therapy.&#xD;
&#xD;
      Data collection is prospective and patient enrollment is expected to occur over 24 months.&#xD;
      The study will enroll patients who are near the 5-year post-diagnosis time point when&#xD;
      decisions on extending endocrine therapy are being made. Patient breast cancer tumors, stored&#xD;
      from surgical collection after initial diagnosis, will be tested with EndoPredict and a&#xD;
      report generated. The provider will convey the report results to the patient and establish a&#xD;
      treatment plan to continue or forgo endocrine therapy. Patients will then be followed for 6&#xD;
      years with data collection every year, and outcomes (distant and local disease recurrence,&#xD;
      second primary breast cancer, etc.) recorded.&#xD;
&#xD;
      The associations between outcomes and treatment, EPclin score and risk category, EP molecular&#xD;
      score, and clinicopathologic features will be investigated in all patients and in&#xD;
      subpopulations (node negative, node positive, treated with or without chemotherapy, etc.).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2029</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Years</target_duration>
  <primary_outcome>
    <measure>Evaluate DRFS of women 5-10 years post diagnosis with ER+, HER2-breast cancer who are low risk according to their EPclin scores</measure>
    <time_frame>10 Years</time_frame>
    <description>The primary objective of this study is to evaluate distant recurrence-free survival (DRFS) between years 5 and 10 post-diagnosis of women with ER+, HER2- breast cancer who are classified as low risk according to their EPclin score and who did not receive extended endocrine therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate DRFS between years 5 and 10 post-diagnosis in women classified as low risk according to their EPclin who received extended endocrine therapy</measure>
    <time_frame>10 Years</time_frame>
    <description>Evaluate DRFS between years 5 and 10 post-diagnosis in women classified as low risk according to their EPclin who received extended endocrine therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate DRFS between years 5 and 10 post-diagnosis in women classified as high risk according to their EPclin score based on treatment decisions.</measure>
    <time_frame>10 Years</time_frame>
    <description>Evaluate DRFS between years 5 and 10 post-diagnosis in women classified as high risk according to their EPclin score based on treatment decisions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate adherence to EndoPredict® test results when making decisions regarding extended endocrine therapy</measure>
    <time_frame>1 Year</time_frame>
    <description>Evaluate the proportion of patients classified as EPclin low who forgo extending endocrine and the proportion of EPclin high who extend endocrine therapy beyond 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate adherence to EndoPredict® test results when making decisions regarding extended endocrine therapy according to whether patients received adjuvant chemotherapy.</measure>
    <time_frame>1 Year</time_frame>
    <description>Evaluate the proportion of patients who received adjuvant chemotherapy classified as EPclin low who forgo extending endocrine and those classified as EPclin high who extend endocrine therapy beyond 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate disease-free survival in patients stratified based on EPclin risk classification and actual treatment.</measure>
    <time_frame>10 Years</time_frame>
    <description>Evaluate disease-free survival in patients stratified based on EPclin risk classification and actual treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Compare previous chemotherapy treatment decisions to chemotherapy treatment recommendations based on EndoPredict® risk classification.</measure>
    <time_frame>1 Year</time_frame>
    <description>Compare previous chemotherapy treatment decisions to chemotherapy treatment recommendations based on EndoPredict® risk classification.</description>
  </other_outcome>
  <other_outcome>
    <measure>Repeat all primary and secondary objectives in subsets of patients based on variables such as clinicopathologic features and treatment.</measure>
    <time_frame>10 Years</time_frame>
    <description>Repeat all primary and secondary objectives in subsets of patients based on variables such as clinicopathologic features and treatment.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2800</enrollment>
  <condition>Primary Invasive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with primary invasive ER+ HER2- breast cancer</arm_group_label>
    <description>Distant recurrence-free survival (DRFS) between years 5 and 10 post-diagnosis of women with ER+, HER2- breast cancer who are classified as low risk according to their EPclin score and who did not receive extended endocrine therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational</intervention_name>
    <description>Observational</description>
    <arm_group_label>Patients with primary invasive ER+ HER2- breast cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Approximately 2,800 patients with ER+, HER2- breast cancer will be enrolled in this study&#xD;
        across multiple sites. These patients will include both node-positive and node negative&#xD;
        patients, with a minimum of 1673 patients with low-risk EPclin scores including 1,505 who&#xD;
        forego extended endocrine therapy. Patients will be eligible for the study if they meet the&#xD;
        following inclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  At least 18 years of age at time of enrollment&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  ER+, HER2- breast tumor&#xD;
&#xD;
          -  Stage T1-T3&#xD;
&#xD;
          -  Currently receiving endocrine therapy&#xD;
&#xD;
          -  Are between 4 and 6.5 years post-invasive breast cancer diagnosis&#xD;
&#xD;
          -  Have all available information to produce an EPclin score, including treatment-naïve&#xD;
             tumor stage, nodal status, and sufficient amount of remaining tissue from biopsy or&#xD;
             resection to perform genomic testing (section 9)&#xD;
&#xD;
          -  Patient and physician are willing to consider a change in endocrine therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic disease or currently active additional cancer diagnosis (except non-&#xD;
             melanoma skin cancer) or any second primary breast cancer (includes ductal and/or&#xD;
             lobular carcinoma in situ)&#xD;
&#xD;
          -  Patient received systemic chemotherapy within 1 year of enrollment&#xD;
&#xD;
          -  Currently enrolled in an interventional clinical trial or other clinical trial that&#xD;
             precludes freely making decisions regarding extended endocrine therapy&#xD;
&#xD;
          -  More than 3 positive nodes&#xD;
&#xD;
          -  Received neo-adjuvant treatment (new-adjuvant chemotherapy or neo-adjuvant endocrine&#xD;
             therapy)&#xD;
&#xD;
          -  Are beyond 7 years post-breast cancer diagnosis&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>The primary objective of this study is to evaluate distant recurrence-free survival (DRFS) between years 5 and 10 post-diagnosis of women with ER+, HER2- breast cancer who are classified as low risk according to their EPclin score and who did not receive extended endocrine therapy.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joyce O'Shaunessey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>US Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Megan Roberts</last_name>
    <phone>1-801-581-0073</phone>
    <email>mastle@myriad.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Providence</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Ichihara</last_name>
      <email>Brian.ichihara@providence.org</email>
    </contact>
    <investigator>
      <last_name>Erwin Grussie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter Hematology and Oncology</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Babski</last_name>
      <email>babskik@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Kristie Bobolis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fadi Kayali, MD</last_name>
      <email>ResearchStudyManagers@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Fadi Kayali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Wright, MD</last_name>
      <email>ResearchStudyManagers@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>David Wright, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Augusto Villegas, MD</last_name>
      <email>ResearchStudyManagers@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Augusto Villegas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marilyn Raymond, MD</last_name>
      <email>ResearchStudyManagers@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Marilyn Raymond, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbus Regional Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chelsea Henthorn</last_name>
      <phone>706-780-6234</phone>
      <email>chenthorne@iacthealth.com</email>
    </contact>
    <investigator>
      <last_name>Andrew Pippas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AON Hematology Oncology Clinic</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Alumbaugh</last_name>
      <email>aimee.alumbaugh@aoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Evie Key</last_name>
      <email>evita.key@aoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Castine III, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katherine Colbeck</last_name>
      <email>Katherine.colbeck@baystate.org</email>
    </contact>
    <investigator>
      <last_name>Grace Makari-Judson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zachary Polselli</last_name>
      <email>zpolsel1@hfhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Fowler</last_name>
      <email>jfowler4@hfhs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Haythem Ali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessica Doersam, MBA</last_name>
      <phone>716-845-3019</phone>
      <email>Jessica.Doersam@RoswellPark.org</email>
    </contact>
    <investigator>
      <last_name>Tracey O'Connor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology</name>
      <address>
        <city>Clifton Park</city>
        <state>New York</state>
        <zip>12065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of Central New York, PC</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Appleton</last_name>
      <email>dappleton@Hoacny.com</email>
    </contact>
    <investigator>
      <last_name>Anita Pudusseri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akron General Medical Center</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Catchpole</last_name>
      <phone>330-344-6348</phone>
      <email>CatchpW@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Sonia Sandhu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summa Health</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Mondello</last_name>
      <phone>330-375-6131</phone>
      <email>mondellot@summahealth.org</email>
    </contact>
    <investigator>
      <last_name>Bradley Clifford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Beaver</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <zip>15009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-6413418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Upper St. Clair</name>
      <address>
        <city>Bethel Park</city>
        <state>Pennsylvania</state>
        <zip>15102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Butler Health System Medical Oncology</name>
      <address>
        <city>Butler</city>
        <state>Pennsylvania</state>
        <zip>16001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>steebx@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center - Moon</name>
      <address>
        <city>Coraopolis</city>
        <state>Pennsylvania</state>
        <zip>15108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rometa Pollard, BS</last_name>
      <phone>412-641-5430</phone>
      <email>pollardrr@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Brufsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Passavant North Cranberry (OHA)</name>
      <address>
        <city>Cranberry Township</city>
        <state>Pennsylvania</state>
        <zip>16066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Erie</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Horizon</name>
      <address>
        <city>Farrell</city>
        <state>Pennsylvania</state>
        <zip>16121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufksy, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Greenville</name>
      <address>
        <city>Greenville</city>
        <state>Pennsylvania</state>
        <zip>16125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>steebx@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Indiana</name>
      <address>
        <city>Indiana</city>
        <state>Pennsylvania</state>
        <zip>15701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>steebx@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Arnold Palmer at Norwin</name>
      <address>
        <city>Irwin</city>
        <state>Pennsylvania</state>
        <zip>15642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>steebx@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Murtha</name>
      <address>
        <city>Johnstown</city>
        <state>Pennsylvania</state>
        <zip>15901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer McKeesport</name>
      <address>
        <city>McKeesport</city>
        <state>Pennsylvania</state>
        <zip>15132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ortenzio Cancer Center</name>
      <address>
        <city>Mechanicsburg</city>
        <state>Pennsylvania</state>
        <zip>17050</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
    </contact_backup>
    <investigator>
      <last_name>Adam M Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Monroeville</name>
      <address>
        <city>Monroeville</city>
        <state>Pennsylvania</state>
        <zip>15146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>steebx@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Arnold Palmer at Mt. Pleasant</name>
      <address>
        <city>Mount Pleasant</city>
        <state>Pennsylvania</state>
        <zip>15666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>steebx@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center - Natrona Heights</name>
      <address>
        <city>Natrona Heights</city>
        <state>Pennsylvania</state>
        <zip>15065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rometa Pollard, BS</last_name>
      <phone>412-641-5430</phone>
      <email>pollardrr@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Brufsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center New Castle</name>
      <address>
        <city>New Castle</city>
        <state>Pennsylvania</state>
        <zip>16105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny Health Network</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Bridi</last_name>
      <email>melissa.bridi@ahn.org</email>
    </contact>
    <investigator>
      <last_name>Jane Raymond, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Magee-Women's Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>steebx@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center (UPMC)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center St Margaret</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Passavant (HOA)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Passavant (OHA)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC - St. Clair Hospital - Integrated Cancer Services</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rometa Pollard</last_name>
      <phone>412-641-5430</phone>
      <email>pollardrr@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Brufsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Northwest</name>
      <address>
        <city>Seneca</city>
        <state>Pennsylvania</state>
        <zip>16346</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Uniontown</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Washington</name>
      <address>
        <city>Washington</city>
        <state>Pennsylvania</state>
        <zip>15301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Jefferson</name>
      <address>
        <city>West Mifflin</city>
        <state>Pennsylvania</state>
        <zip>15122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>steebx@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Williamsport</name>
      <address>
        <city>Williamsport</city>
        <state>Pennsylvania</state>
        <zip>17701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Memorial</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17408</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trish Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Blood and Cancer Care Associates</name>
      <address>
        <city>Lancaster</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dhwani Mehta</last_name>
      <email>dmehta@cbcca.net</email>
    </contact>
    <investigator>
      <last_name>Niyati Nathwani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Blood and Cancer Care Associates</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dhwani Mehta</last_name>
      <email>dmehta@cbcca.net</email>
    </contact>
    <investigator>
      <last_name>Niyati Nathwani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Cancer Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tracy Stewart</last_name>
      <email>Tracy.Stewart2@BMHCC.org</email>
    </contact>
    <investigator>
      <last_name>Phillip Lammers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristy Long, MD</last_name>
      <email>Kristy.Long@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Erika Hamilton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Houston Methodist</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Toniva Boone</last_name>
      <email>tdboone@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Priya Ramshesh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hope Cancer of Texas</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela Salazar</last_name>
      <email>gabriela.salazar@uthct.edu</email>
    </contact>
    <contact_backup>
      <last_name>Dana Gorbett</last_name>
      <email>peggy.gorbett@uthct.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Arielle Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 26, 2019</study_first_submitted>
  <study_first_submitted_qc>July 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ER+ and HER2- Breast Cancer patients</keyword>
  <keyword>Extended Endocrine Therapy</keyword>
  <keyword>EndoPredict</keyword>
  <keyword>Additional Relevant MeSH terms:</keyword>
  <keyword>Breast Neoplasms</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Breast Diseases</keyword>
  <keyword>Skin Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

